1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited

LALPATHLAB.BO
Dr. Lal PathLabs LimitedIN flagBombay Stock Exchange
1,679.60
INR
-7.05
- -
280.38BMarket Cap

Total Valuation

Dr. Lal PathLabs Limited carries a market capitalization of 280.38B, placing it among publicly traded companies globally. Its enterprise value stands at 208.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap280.38B
Enterprise Value208.26B

Share Statistics

Dr. Lal PathLabs Limited currently has 166.98M shares outstanding.

Shares Outstanding166.98M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Dr. Lal PathLabs Limited trades at a trailing price-to-earnings ratio of 61.90. The price-to-sales ratio is 10.79, and the price-to-book ratio stands at 9.45.

PE Ratio61.90
PS Ratio10.79
PB Ratio9.45
P/TBV Ratio12.18
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Dr. Lal PathLabs Limited trades at an EV/EBITDA multiple of 24.75 and an EV/FCF ratio of 1,506.23. The EV/Sales ratio of 10.25 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.75 provides insight into valuation relative to core operating earnings.

EV / Sales10.25
EV / EBITDA24.75
EV / EBIT24.75
EV / FCF1,506.23

Financial Position

Dr. Lal PathLabs Limited maintains a current ratio of 3.48, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.83, indicating elevated leverage, while an interest coverage ratio of 46.74 demonstrates strong ability to service its debt obligations.

Current Ratio3.48
Quick Ratio2.95
Debt / Equity7.83
Debt / EBITDA0.24
Interest Coverage46.74

Financial Efficiency

Dr. Lal PathLabs Limited posts a return on equity of 16.61 and a return on invested capital of 25.52.

Return on Equity (ROE)16.61
Return on Assets (ROA)12.08
Return on Invested Capital (ROIC)25.52
Return on Capital Employed (ROCE)15.56
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover7.16

Taxes

Over the trailing twelve months, Dr. Lal PathLabs Limited has paid 1.08B in income taxes, reflecting an effective tax rate of 23.19.

Income Tax1.08B
Effective Tax Rate23.19

Stock Price Statistics

Dr. Lal PathLabs Limited's stock has gained approximately 17.7221% over the past 52 weeks. The 50-day moving average sits at 1,595.97, while the 200-day moving average is 1,495.80.

Beta (5Y)N/A
52-Week Price Change17.7221%
50-Day Moving Average1,595.97
200-Day Moving Average1,495.80
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Dr. Lal PathLabs Limited generated 20.32B in revenue and converted that into 3.54B in net income, yielding earnings per share of 21.39. EBITDA reached 8.41B, while operating income came in at 8.41B.

Revenue20.32B
Gross Profit17.46B
Operating Income8.41B
Pretax Income4.65B
Net Income3.54B
EBITDA8.41B
EBIT8.41B
Earnings Per Share (EPS)21.39

Balance Sheet

Dr. Lal PathLabs Limited holds 13.31B in cash and equivalents against 1.99B in total debt, resulting in a net debt position of -2.43B. Total book value stands at 23.20B, with working capital of 11.16B providing operational flexibility.

Cash & Cash Equivalents13.31B
Total Debt1.99B
Net Debt-2.43B
Equity (Book Value)23.20B
Book Value Per Share139.05
Working Capital11.16B

Margins

Dr. Lal PathLabs Limited operates with a gross margin of 85.90, reflecting its pricing power and cost economics. The operating margin of 41.40 and net profit margin of 17.43 provide insight into operational efficiency.

Gross Margin85.90
Operating Margin41.40
Pretax Margin22.91
Profit Margin17.43
EBITDA Margin41.40

Stock Splits

Dr. Lal PathLabs Limited's most recent stock split took place on December 19, 2025 with a 1:2 split ratio.

Last Split Date12/19/2025
Split Ratio1:2

Scores

Dr. Lal PathLabs Limited posts an Altman Z-Score of 25.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score25.56